Reactive Species Risk Assessment Using Optimized HET-CAM Safety Evaluation of Feed Gas-Modified Gas Plasma Technology and Anticancer Drugs-Reference-Cited by-同舟云学术

Reactive Species Risk Assessment Using Optimized HET-CAM Safety Evaluation of Feed Gas-Modified Gas Plasma Technology and Anticancer Drugs

Published:2024-06-26 Issue:27 Volume:16 Page:34480-34495
ISSN:1944-8244
Container-title:ACS Applied Materials & Interfaces
language:en
Short-container-title:ACS Appl. Mater. Interfaces

Author:

Berner Julia¹²^ORCID,Herold Luise²³,Martinet Alice¹²,Miebach Lea²,von Woedke Thomas²^ORCID,Weltmann Klaus-Dieter²,Emmert Steffen¹,Boeckmann Lars¹,Bekeschus Sander¹²^ORCID

Affiliation:

1. Clinic and Policlinic for Dermatology and Venerology, Rostock University Medical Center, Strempelstr. 13, 18057 Rostock, Germany

2. ZIK Plasmatis, Leibniz Institute for Plasma Science and Technology (INP), a Member of the Leibniz Health Technologies Research Alliance, Felix-Hausdorff-Str. 2, 17489 Greifswald, Germany

3. Department of Oral, Maxillofacial, and Plastic Surgery, Greifswald University Medical Center, Ferdinand-Sauerbruch-Str., 17475 Greifswald, Germany

Funder

Bundesministerium f?r Bildung und Forschung

European Regional Development Fund

Deutsche Forschungsgemeinschaft

Ministerium f?r Bildung, Wissenschaft und Kultur Mecklenburg-Vorpommern

Ministry for Commerce and Energy, Germany

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsami.4c04039

Reference67 articles.

1. Cancer Statistics, 2021

2. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

3. Cancer drug resistance: an evolving paradigm

4. Cold atmospheric plasma: Novel opportunities for tumor microenvironment targeting

5. Emerging innovations in cold plasma therapy against cancer: A paradigm shift